Imatinib and type 2 diabetes

Endocrine Practice

Volumn 13, Issue 2, 2007, Pages 126-130

  Dingli, David ^a   Wolf, Robert C ^a   Vella, Adrian ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ANIMAL; ARTICLE; BLOOD; BODY MASS; BODY WEIGHT; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MEDICAL RECORD; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; STATISTICS; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447329895     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.2.126     Document Type: Article

References (15)

1. Madhusudan S, Ganesan TS. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem. 2004;37:618-635.
2. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Altered functional variants of TGFB-inducible transcription factor KLF11 are associated with diabetes [abstract]. Diabetologia. 2004;47:P212.
3. Neve B, Fernandez-Zapico ME, Ashkenazi-Katalan V, et al. Role of transcription factor KLF11 and its diabetes-associated gene variants in pancreatic beta cell function. Proc Natl Acad Sci U S A. 2005;102:4807-4812.
4. Cook T, Gebelein B, Mesa K, Mladek A, Urrutia R. Molecular cloning and characterization of TIEG2 reveals a new subfamily of transforming growth factor-beta-inducible Sp1-like zinc finger-encoding genes involved in the regulation of cell growth. J Biol Chem. 1998;273: 25929-25936.
5. Ellenrieder V, Buck A, Harth A, et al. KLF11 mediates a critical mechanism in TGF-beta signaling that is inactivated by Erk-MAPK in pancreatic cancer cells. Gastroenterology. 2004;127:607-620.
6. Jonuleit T, van der Kuip H, Miething C, et al. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. Blood. 2000;96:1933-1939.
7. Couzin J. Diabetes research: researchers puzzle over possible effect of Gleevec. Science. 2005;307(5716):1711.
8. Lassila M, Jandeleit-Dahm K, Seah KK, et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol. 2005;16:363-373.
9. Lassila M, Allen TJ, Cao Z, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:935-942.
10. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment. J Clin Oncol. 2004;22:4653-4655.
11. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med. 2005;352:1049-1050.
12. Imano E, Kanda T, Ishigami Y, et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol. 1998;28:189-193.
13. Koivisto VA, Pelkonen R, Cantell K. Effect of interferon on glucose tolerance and insulin sensitivity. Diabetes. 1989;38:641-647.
14. Dalla Man C, Campioni M, Polonsky KS, et al. Two-hour seven-sample oral glucose tolerance test and meal protocol: minimal model assessment of beta-cell responsivity and insulin sensitivity in nondiabetic individuals. Diabetes. 2005;54:3265-3273.
15. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet. 2003;4:257-291.